DRTX


Actavis Says ‘Let’s Make A Deal’

I wrote about generic and specialty drug company Actavis plc (NYSE:ACT) a while back detailing the rumored love triangle between them, Allergan (NYSE:AGN), …

Durata Therapeutics: Moving To Neutral On Likely Closure Of Actavis Takeout, Says Roth Capital

In a research report issued today, Roth Capital analyst Ed Arce downgraded shares of Durata Therapeutics (NASDAQ:DRTX) from Buy to Neutral, while maintaining his $23 …

Durata To Be Acquired by Actavis; We View The Cash Bid As Reasonable, Says Roth Capital

In a research report issued yesterday, Roth Capital analyst Ed Arce maintained a Buy rating on Durata Therapeutics (NASDAQ:DRTX) and reduced his price …

We See Durata Shares Regaining Momentum, Says Roth Capital

In a research report issued today, Roth Capital analyst Ed Arce assigned a Buy rating on Durata Therapeutics (NASDAQ:DRTX) with a $26 price target, …

Durata Therapeutics: We Recommend Adding To Positions At These Levels, Says Roth Capital

In a research report issued today, Roth Capital analyst Ed Arce maintained a Buy rating on Durata Therapeutics (NASDAQ:DRTX) with a $26 price …

Roth Capital Affirms Buy On Durata Therapeutics Following License Agreement With Angelini

Last week, July 30, Durata Therapeutics (DRTX) announced a commercialization agreement for Dalvance (dalbavancin) with Angelini across much of Southern and Eastern Europe, Russia and Turkey. The …

Roth Capital Reaffirms Buy On Durata As It Begins Shipping Dalvcance To Its Distributors

In reaction to Durata Therapeutics’s (DRTX) announcement that it has began shipping Dalvance to its distributors, Roth Capital analyst Ed Arce reaffirmed a …

Roth Capital Affirms Buy Rating On Durata Therapeutics, Raises PT To $28

In a research report released today, Roth Capital analyst Ed Arce raised his price target on Durata Therapeutics (DRTX) to $28 (from $24), while maintaining a Buy rating on the stock. The new price target …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts